PriceTargets.com logo

Evelo Biosciences - EVLO Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.17
  • Forecasted Upside: 1,467.66%
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.20 As of 03/24/2023 11:42 AM ET
▼ -0.0037 (-1.80%)

This chart shows the closing price for EVLO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evelo Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVLO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVLO

Analyst Price Target is $3.17
▲ +1,467.66% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Evelo Biosciences in the last 3 months. The average price target is $3.17, with a high forecast of $5.00 and a low forecast of $2.00. The average price target represents a 1,467.66% upside from the last price of $0.20.

This chart shows the closing price for EVLO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 polled investment analysts is to hold stock in Evelo Biosciences. This rating has held steady since October 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
9/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
3/29/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/25/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
2/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
3/24/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/17/2023BMO Capital MarketsLower Target$10.00 ➝ $5.00Low
3/16/2023Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
2/15/2023Morgan StanleyLower TargetEqual Weight$4.00 ➝ $2.00Low
2/1/2023Jefferies Financial GroupDowngradeBuy ➝ UnderperformLow
11/16/2022Chardan CapitalDowngradeBuy ➝ Neutral$2.50Low
9/9/2022Morgan StanleyLower TargetEqual Weight$5.00 ➝ $4.00Low
8/24/2022Morgan StanleyLower TargetEqual Weight$6.00 ➝ $5.00Low
8/15/2022Chardan CapitalLower TargetBuy$12.00 ➝ $5.00Low
11/2/2021JMP SecuritiesLower TargetMarket Outperform$44.00 ➝ $41.50High
11/1/2021Chardan CapitalUpgradeNeutral ➝ Buy$12.00Medium
10/31/2021BMO Capital MarketsReiterated RatingBuy$23.00Medium
9/28/2021Jefferies Financial GroupLower TargetBuy$18.00 ➝ $14.00High
9/27/2021JMP SecuritiesReiterated RatingBuy$44.00Medium
7/30/2021Chardan CapitalLower TargetNeutral$15.00 ➝ $12.00High
7/9/2021Chardan CapitalInitiated CoverageHold$15.00Low
7/1/2021Chardan CapitalReiterated RatingNeutralLow
6/23/2021JMP SecuritiesBoost TargetPositive ➝ Market Outperform$36.00 ➝ $38.00High
6/23/2021Cantor FitzgeraldInitiated CoverageOverweight$28.00High
5/3/2021Morgan StanleyLower TargetEqual Weight$14.00 ➝ $13.00High
4/12/2021Jefferies Financial GroupUpgradeHold ➝ Buy$11.00 ➝ $18.00High
3/12/2021Chardan CapitalBoost TargetNeutral$10.00 ➝ $15.00Low
1/25/2021JMP SecuritiesBoost TargetPositive ➝ Outperform$27.00 ➝ $36.00High
1/19/2021Morgan StanleyBoost TargetEqual Weight$6.00 ➝ $14.00Low
12/23/2020JMP SecuritiesInitiated CoverageOutperform$27.00 ➝ $27.00N/A
11/11/2020Morgan StanleyLower TargetEqual Weight$8.00 ➝ $6.00Low
7/2/2020BMO Capital MarketsLower TargetOutperform$21.00 ➝ $17.00Medium
5/21/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$8.00Medium
5/12/2020BMO Capital MarketsLower TargetOutperform$24.00 ➝ $21.00High
5/12/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$18.00 ➝ $6.00High
3/20/2020Chardan CapitalReiterated RatingHoldHigh
2/14/2020CowenReiterated RatingBuyHigh
9/19/2019Chardan CapitalReiterated RatingNeutralHigh
5/2/2019CowenReiterated RatingBuyLow
5/2/2019Chardan CapitalReiterated RatingHold$10.00Low
4/30/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$18.00Medium
2/15/2019Chardan CapitalReiterated RatingHold$10.00Medium
1/29/2019Chardan CapitalInitiated CoverageNeutral$10.00Low
12/3/2018JMP SecuritiesReiterated RatingBuy$25.00High
10/11/2018Morgan StanleyBoost TargetOverweight$29.00 ➝ $30.00Low
6/4/2018CowenInitiated CoverageOutperformLow
6/4/2018Morgan StanleyInitiated CoverageOverweightLow
6/4/2018BMO Capital MarketsInitiated CoverageOutperform$26.00Low
6/4/2018JMP SecuritiesInitiated CoverageOutperform$25.00Low
(Data available from 3/24/2018 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/26/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/25/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/25/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/24/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/24/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/23/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
2/22/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2023

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Evelo Biosciences logo
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $0.20
Low: $0.20
High: $0.22

50 Day Range

MA: $0.75
Low: $0.21
High: $1.38

52 Week Range

Now: $0.20
Low: $0.20
High: $4.36

Volume

16,709 shs

Average Volume

167,149 shs

Market Capitalization

$22.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Evelo Biosciences?

The following equities research analysts have issued stock ratings on Evelo Biosciences in the last twelve months: BMO Capital Markets, Cantor Fitzgerald, Chardan Capital, Jefferies Financial Group Inc., and Morgan Stanley.
View the latest analyst ratings for EVLO.

What is the current price target for Evelo Biosciences?

3 Wall Street analysts have set twelve-month price targets for Evelo Biosciences in the last year. Their average twelve-month price target is $3.17, suggesting a possible upside of 1,467.7%. BMO Capital Markets has the highest price target set, predicting EVLO will reach $5.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $2.00 for Evelo Biosciences in the next year.
View the latest price targets for EVLO.

What is the current consensus analyst rating for Evelo Biosciences?

Evelo Biosciences currently has 1 sell rating and 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EVLO, but not buy more shares or sell existing shares.
View the latest ratings for EVLO.

What other companies compete with Evelo Biosciences?

Other companies that are similar to Evelo Biosciences include AgeX Therapeutics, Biora Therapeutics, SELLAS Life Sciences Group, Metacrine and TFF Pharmaceuticals. Learn More about companies similar to Evelo Biosciences.

How do I contact Evelo Biosciences' investor relations team?

Evelo Biosciences' physical mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company's listed phone number is (617) 577-0300 and its investor relations email address is [email protected] The official website for Evelo Biosciences is www.evelobio.com. Learn More about contacing Evelo Biosciences investor relations.